The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting

Perfusion

Volumn 18, Issue 5, 2003, Pages 283-289

  Grima, Carmel ^a,b  

^a ST LUKE S HOSPITAL   (Malta)

^b NONE   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HEPARIN; PROTAMINE SULFATE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG RESPONSE; ERYTHROCYTE CONCENTRATE; HEMOSTASIS; HUMAN; MALE; PERICARDIAL EFFUSION; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; FIBRINOGEN; HEMOSTASIS; HEPARIN; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POINT-OF-CARE SYSTEMS;

EID: 0242468164     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659103pf668oa     Document Type: Article

References (16)

1. Keck WM. Center for Transgene Research. Haemostasis - introduction and goals. Retrieved 17th October 2002, from http://www.nd.edu/~transgen/research/hemostasis.html
2. Hirsh J, Warkentin TE, Shaughnessy, SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: S64-S94.
3. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980; 286: 456-60.
4. Johnell M, Elgue G, Larsson R, Larsson A, Thelin S, Siegbahn MH. Coagulation, fibrinolysis and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002; 124: 321-32.
5. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circuit. Anesthesiology 1975; 43: 346-54.
6. Brinks HJ, Weerwind PW, Bogdan S, Verbruggen H, Brouwer MH. Does heparin pre-treatment affect the haemostatic system during and after cardiopulmonary bypass? Perfusion 2001; 16: 3-12.
7. Nicholson, SC, Keeling DM, Sinclair ME, Evans RD. Heparin pre-treatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth 2001; 87: 844-47.
8. Ray MJ, Perrin EJ, Hawson GA. Proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of re-agents and improved estimation of heparin concentrations. Blood Coagul Fibrinolysis 1996; 5: 515-21.
9. Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998; 65: 712-18.
10. Gelb AB, Roth RI, Levin J et al. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Path 1996; 106: 87-99.
11. Perrin EJ, Ray MJ, Hawson GA. The role of von Willebrand factor in haemostasis and blood loss during and after cardiopulmonary bypass surgery. Blood Coagul Fibrinolysis 1995; 6: 650-58.
12. Hunt BJ. Desmopressin and bleeding during invasive surgery. Eur J Anaesth 1997; 14: 42-49.
13. Holdright DR, Hunt BJ, Parratt R et al. The effect of cardiopulmonary bypass on systemic and coronary levels of von Willebrand factor. Eur J Cardiothorac Surg 1995; 9: 18-21.
14. Kuitunen A, Hynynen M, Salmenpera M et al. Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. Br J Anaesth 1993; 70: 173-80.
15. Pradhan MJ, Fleming JS, Nkere UU, Arnold J, Wildevuur CH, Taylor KM. Clinical experience with heparin-coated CPB circuits. Perfusion 1991; 6: 235-42.
16. DeHaan J, Boonstra PW, Tabuchi N, van Oeveren W, Ebels T. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. J Thorac Cardiovasc Surg 1996; 111: 272-75.